Nicola Ferrari

Company: Astex Pharmaceuticals

Job title: Research Associate- Translational R&D

Seminars:

The Clinical IAP Antagonist ASTX660 Drives Anti-Tumor Immunity in T Cell Lymphoma 11:30 am

ASTX660 is a potent, non-peptidomimetic antagonist of cIAP1/2 and XIAP, which has demonstrated preliminary evidence of single agent clinical activity in T cell lymphoma (TCL) patients To investigate the mechanism of action behind the single agent activity seen in the clinic we have used a comprehensive translational approach via the integration of in vitro coculture…Read more

day: Day One